A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

NCT06551324 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Interventions

DRUG: PF-06821497
DRUG: Docetaxel
DRUG: Enzalutamide

Sponsor

Pfizer